WP
JANX icon

Woodline Partners’s Janux Therapeutics JANX Stock Holding History

Woodline Partners’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.68M Sell
370,032
-368,000
-50% -$5.33M 0.02% 665
2026
Q1 		$10.3M Sell
738,032
-289,189
-28% -$3.97M 0.04% 503
2025
Q4 		$14.2M Buy
1,027,221
+283
+0% +$6.66K 0.05% 378
2025
Q3 		$25.1M Sell
1,026,938
-215,000
-17% -$5.24M 0.12% 230
2025
Q2 		$28.7M Sell
1,241,938
-215,157
-15% -$5.67M 0.15% 205
2025
Q1 		$39.3M Sell
1,457,095
-395,092
-21% -$14.9M 0.26% 121
2024
Q4 		$99.2M Buy
1,852,187
+251,924
+16% +$13.3M 0.67% 15
2024
Q3 		$72.7M Buy
1,600,263
+1,299,438
+432% +$56.5M 0.61% 30
2024
Q2 		$12.6M Buy
300,825
+270,977
+908% +$12.7M 0.12% 226
2024
Q1 		$1.12M Buy
+29,848
New +$650K 0.01% 455
2023
Q4 		– Sell
-85,708
Closed -$864K – 567
2023
Q3 		$864K Sell
85,708
-51,592
-38% -$595K 0.01% 459
2023
Q2 		$1.63M Hold
137,300
– – 0.02% 453
2023
Q1 		$1.66M Sell
137,300
-368,064
-73% -$6.13M 0.02% 434
2022
Q4 		$6.66M Buy
505,364
+105,183
+26% +$1.54M 0.09% 272
2022
Q3 		$5.42M Buy
400,181
+113,798
+40% +$1.52M 0.08% 276
2022
Q2 		$3.5M Buy
286,383
+8,060
+3% +$95.4K 0.05% 311
2022
Q1 		$3.99M Buy
278,323
+48
+0% +$785 0.06% 267
2021
Q4 		$5.49M Sell
278,275
-21,756
-7% -$456K 0.08% 271
2021
Q3 		$6.49M Sell
300,031
-34,229
-10% -$985K 0.11% 221
2021
Q2 		$8.34M Buy
+334,260
New +$7.44M 0.16% 152

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Woodline Partners's JANX Position: Q2 2026 in Review

Woodline Partners reduced its Janux Therapeutics (JANX) stake by 50% in Q2 2026, selling an estimated $5.33M and leaving 370,032 shares worth $5.68M. The position accounts for 0.02% of the portfolio, ranked #665.

Woodline Partners first reported a position in JANX in Q2 2021 and has held it in 20 quarters since. The position peaked at $99.2M in Q4 2024. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Woodline Partners held 370,032 shares of Janux Therapeutics worth $5.68M as of Q2 2026.
  • Woodline Partners sold 368,000 Janux Therapeutics shares in Q2 2026, an estimated $5.33M.
  • Janux Therapeutics made up 0.02% of Woodline Partners's portfolio in Q2 2026, its #665 holding.
  • Woodline Partners first reported a position in Janux Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • Woodline Partners's Janux Therapeutics position peaked at $99.2M in Q4 2024.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.